Table 1.
Clinical studies concerning SFRP5 and WNT5A in obesity, T2DM and CHD
| Disorders | SFRP5 | WNT5A | IR | References |
|---|---|---|---|---|
| Obesity | ↓↓↓ | / | (‐) | Hu ZP et al36 |
| ↓↓↓ | ↑↑↑a | (‐) | Tan et al37 | |
| ↓↓↓ | / | (‐) | Hu WJ et al38 | |
| ↑↑↑a | ↑↑↑ | / | Schulte et al40 | |
| ↓↓↓a | ↑↑↑ | / | Catalan et al41 | |
| ↓↓↓ | ↑↑↑ | / | Akoumianakis et al39 | |
| T2DM | ↓↓↓ | / | (‐) | Hu ZP et al36 |
| ↓↓↓ | / | (‐) | Hu WJ et al38 | |
| ↓↓↓ | / | (‐) | Cheng et al48 | |
| ↓↓↓ | / | (‐) | Carstensen‐Kirberg et al49 | |
| ↑↑↑ | / | None | Canivell et al50 | |
| ↑↑↑ | ↓↓↓ | None | lu et al51 | |
| CHD | ↓↓↓ | / | (‐) | Miyoshi et al34 |
| ↓↓↓ | ↑↑↑ | / | Akoumianakis et al39 | |
| STEMI | ↑↑↑ | / | (‐) | Du et al55 |
↑↑↑ indicates that the SFRP5 levels or WNT5A levels were increased in patients with obesity, T2DM and CHD compared with healthy controls, respectively. ↓↓↓ indicates that the SFRP5 levels or WNT5A levels were decreased in patients with obesity, T2DM and CHD compared with healthy controls, respectively. (‐) indicates that the SFRP5 levels were negatively correlated with IR. None indicates that there were no relationships between the SFRP5 levels and IR. / indicates that the data were not mentioned in this study.
Abbreviations: CHD, coronary heart disease; IR, insulin resistance; SFRP5, secreted frizzled‐related protein 5; STEMI, ST‐segment elevation myocardial infarction; T2DM, type 2 diabetes mellitus; WNT5A, wingless‐type family member 5A.
Indicates that there was no statistical significance.